U.S. Stock Insider Trading | Vera Therapeutics Disclosed 7 Insider Transactions on February 25

K-LinePoet · 2026-03-15T21:46:27+00:00

On February 25, 2026, Vera Therapeutics disclosed multiple insider transactions, with director Fordyce Marshall selling 16,900 shares, and other executives also selling their shares. The company focuses on developing therapeutic drugs for immune diseases, with its primary candidate product being atacicept.

K-LinePoet

2026-03-15 21:46:27

Abstract generation in progress

On February 25, 2026, Vera Therapeutics (VERA) disclosed seven insider transactions. Director Fordyce Marshall sold 16,900 shares on February 23, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 25, 2026	Executive	Young Joseph R	February 23, 2026	Sell	3,117	41.98	$130,900
February 25, 2026	Executive	Grant Sean	February 23, 2026	Sell	4,949	41.98	$207,800
February 25, 2026	Executive	JOHNSON DAVID LEE	February 23, 2026	Sell	2,579	41.98	$108,300
February 25, 2026	Executive	Skelton Laurence Matthew	February 23, 2026	Sell	1,582	41.98	$66,400
February 25, 2026	Executive	Turner William D.	February 23, 2026	Sell	2,187	41.98	$91,800
February 25, 2026	Director	Fordyce Marshall	February 23, 2026	Sell	16,900	41.98	$710,600
February 25, 2026	Executive	Brenner Robert	February 23, 2026	Sell	2,151	41.98	$90,300
December 17, 2025	Executive	Turner William D.	December 15, 2025	Sell	10,000	50.08	$500,800
December 17, 2025	Executive	Turner William D.	December 15, 2025	Buy	10,000	15.53	$155,300
December 15, 2025	Director	ENRIGHT PATRICK G	December 11, 2025	Buy	5,882	42.50	$250,000

【Company Information】

Vera Therapeutics, Inc. was originally incorporated in Delaware in May 2016 under the name CDF Therapeutics, Inc., and renamed Vera Therapeutics, Inc. in April 2020. The company is a late-stage biotechnology firm focused on developing and commercializing therapies for patients with severe immune diseases. Its lead candidate, atacicept, is a self-administered fusion protein that blocks B lymphocyte stimulators and proliferation-inducing ligands, with best-in-class potential for treating IgA nephropathy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.